Eppendorf Award for Young European Investigators opens for entry

Deadline is 15 January 2012

Young researchers working in Europe are invited to apply for the Eppendorf Award for Young European Investigators.

Researchers who are less than 35 have until 15 January 2012 to apply.

The award, inaugurated in 1995, acknowledges outstanding contributions to biomedical research in Europe based on methods of molecular biology, including novel analytical concepts.

An independent expert committee chaired by Kai Simons of the Max Planck Institute for Molecular Cell Biology and Genetics, in Dresden, Germany, will choose the winner.

The successful entrant will receive €15,000 in prize money and an invitation to the prize-giving ceremony at the EMBL Advanced Training Centre in Heidelberg, Germany on 9 May 2012.

In addition, he/she will be invited to Eppendorf in Hamburg and coverage of his/her work will be published in Nature magazine and in a podcast.

The official registration portal is at www.eppendorf.com/award/application. Only online registrations will be accepted.

Full details on the Eppendorf Award, the selection criteria and past award winners, are available at www.eppendorf.com/award.

You may also like

Research & Development

Eppendorf strives to ensure that all labs are smart, safe and stress-free

Eppendorf is a leading life science company that develops and sells instruments, consumables and services for liquid handling, sample handling and cell handling in laboratories worldwide
Manufacturing

Eppendorf launches New Brunswick S41i incubator shaker

Six-sided direct-heating profile provides gentle convection circulation of the chamber
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)

With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Research & Development

Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases

The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Subscribe now